<h3>Avoiding influenza may reduce the risk of influenza-related heart attack3:</h3>
META-ANALYSIS: Estimates of interventional efficacy in secondary prevention of myocardial infarction3

<h3>Avoiding influenza can help reduce the risk of severe outcomes4:</h3>
In 124,503 people with type 2 diabetes, from 2003-2010, influenza vaccination was associated with substantial reductions in hospital admission rates.4

aNot significant. 
 AMI=acute myocardial infarction.

<h3>The CDC Advisory Committee on Immunization Practices (ACIP) recommends routine annual influenza vaccination for all eligible persons aged ≥6 months5:</h3>
While the ACIP recommends all persons aged 6 months and older who do not have contraindications receive an influenza vaccine, it is especially important for populations who are at increased risk for severe illness and medical complications. These include, but are not limited to, adults aged 50 years and older and people who have5:
<ul>
 <li>Chronic pulmonary disorders (including asthma)</li>
 <li>Cardiovascular diseases (excluding isolated hypertension)</li>
 <li>Metabolic disorders (including diabetes)</li>
</ul>
<h3>The ACIP recommends being vaccinated against influenza by the end of October each year5:</h3>
Since the timing of the influenza season is unpredictable and vaccine-induced immunity may wane over time, the ACIP suggests the following timing recommendations5:
DON’T VACCINATE TOO EARLY: Early vaccination in July or August for nonpregnant adults should be avoided because it may be associated with decreased vaccine effectiveness before the end of the influenza season, especially for older adults.5
OFFER VACCINATIONS THROUGH FLU SEASON: Vaccination should continue to be offered as long as influenza viruses are circulating.5

References

Flu and Vaccination

INFLUENZA

VACCINES

<h2>Our Heritage</h2>
For over 100 years, Sanofi Pasteur has been committed to extending the life-saving power of vaccination as broadly as possible. Our history is grounded in life science pioneers who discovered how infectious diseases work. They unlocked the public health potential of vaccination and developed efficient mass production methods to ensure the broadest access to vaccines.
Our portfolio of vaccines, ranging from cholera, dengue fever, diphtheria, to&nbsp;haemophilus influenzae&nbsp;type b, polio, pertussis, tetanus, hepatitis A and B, meningococcal meningitis, influenza, to name a few, offer protection against a wide range of infectious diseases to people around the world. We work hand-in-hand with public health partners so our vaccines can help protect as many as half a billion lives annually.

Our team brings their passion to discover and develop vaccines to enhance protection for children, adolescents and adults alike. Our researchers are seeking effective vaccines to extend the benefits of vaccination to a number of infectious diseases, such as respiratory syncytial virus infections which can cause severe lung infections among children, including bronchiolitis and pneumonia.
We are not standing still with our existing vaccines. Our latest generation of 6-in-1 pediatric vaccines helps improve childhood immunization and reduces the number of vaccination visits for infants while improving comfort for children and reducing anxiety for parents1.
With the public health community we are actively involved in addressing funding, access and distribution challenges that inhibit vaccinations in countries with underdeveloped infrastructure. This is what drives us forward and gives us purpose.

Together with our public and private partners, we are all driven by a common goal:

Reference

Sanofi Pasteur at Glance

<h3>Your older patients with cardiovascular diseases are at increased risk of a first major cardiovascular event when diagnosed with influenza2:</h3>

Flu and Cardiovascular Disease

In subjects at least 40 years of age or older2,a
an=1227

~10x increased risk of a first heart attack

black

In subjects 40 years of age or older2,b
bn=762

~8x increased risk of a first stroke

Study limitations: Individual noninfluenza respiratory virus impact and age impact on vascular events were not investigated. During the study period there were changes in microbiological testing practices (eg, PCR was not widely used in 2004). The day after the date of respiratory sampling was used as the start of the risk period.2
<h3>The American Heart Association urges eligible individuals aged 6 months and older to get their annual flu shot3:</h3>
Protecting against influenza can help reduce the risk of cardiovascular events and can help keep your patients out of the hospital.4

<h3>Your patients with chronic respiratory conditions are at increased risk for dangerous complications when diagnosed with influenza2-5</h3>

Flu and Respiratory Disease

<h3>In a study of the correlation between influenza and pneumonia, participants with symptomatic influenza had6:</h3>

3234 children aged 0-14 years old were enrolled in this Nicaraguan study.6,a
&nbsp;
Study limitations:&nbsp;Generalizability to US children may be limited. Given pneumonia is a rare outcome, the categorization by subtype resulted in fewer cases per strata, which may limit statistical power.6

~8x (95% CI: 4.8-14.5) 
 
 increased risk of developing pneumonia within a week following influenza infection

<h3>The American Lung Association urges eligible individuals aged 6 months and older to get their annual flu shot7</h3>
Protecting against influenza can help reduce the risk of pneumonia and can help keep your patients out of the hospital.2,4,8

As a health journey partner, we at Sanofi Pasteur are proud that our vaccines can help to protect people and their loved ones from a wide range of severe infectious diseases at every stage of life.

Sanofi Pasteur partners with the public health, medical and scientific communities to improve access to life-protecting vaccines and increase vaccination coverage, while striving to develop new and improved vaccines to enhance health and well-being.

<h3>Your patients with diabetes are at increased risk of dangerous complications when diagnosed with influenza2-4:</h3>

Flu and Diabetes

<h3>Patients living with diabetes are at increased risk for influenza complications2-4:</h3>

<h3>~3x&nbsp;(95% CI: 2.04-4.71) 
 more likely to be&nbsp;hospitalized2</h3>
<h3>~4x&nbsp;(95% CI: 1.29-14.3) 
 more likely to be&nbsp;admitted tothe ICU2</h3>
Study design2 Subjects:162 patients aged &lt;1 to 85 years Study period:May 25–July 1, 2009 Study limitations:This study was limited to those with PCR-confirmed influenza A H1N1. Medical history was obtained solely by patient interview.

<h3>~2x&nbsp;(95% CI: 1.5-3.6) 
 more likely&nbsp;to die&nbsp;after influenza hospitalization</h3>
Study design4 Subjects:196 patients aged 18 and older Study period:April 29, 2009–March 31, 2010 Study limitations:Underreporting and misclassification of outcome or risk factors are possible and might conceal the real disease burden. Study period was during H1N1 pandemic.

<h3>74%&nbsp;(95% CI: 2.15-3.74, p &lt;0.05) 
 increase in abnormal glycemic events5</h3>
Study design:Patient generated health data and medical claims were analyzed for 167,672 patients aged 18 and older Study period:&nbsp;2016–2017 influenza season Study limitations:The analysis focused on adults with commercial insurance and does not fully represent older people with diabetes within the United States or at-risk underserved populations.

<h3>The American Diabetes Association® urges eligible individuals aged 6 months and older to get their annual flu shot6:</h3>
Protecting against influenza can help your patients with diabetes avoid influenza-related complications, such as hospitalization and death.2-4,7

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Influenza

Latest Articles

Flu and Vaccination

Sanofi Pasteur at Glance

Flu and Cardiovascular Disease

Flu and Respiratory Disease

Sanofi Pasteur at Glance

Flu and Diabetes